Clinical significance of CD155 expression in human pancreatic cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Anticancer Research

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 25862891
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

  2013cited by this paper
• Therapeutic advances in pancreatic cancer.

  2013cited by this paper
• The role of Necl-5 in the invasive activity of lung adenocarcinoma.

  2013cited by this paper
• Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti‐tumour effect in vivo

  2013cited by this paper
• Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer

  2013cited by this paper
• PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• The TIGIT/CD226 Axis Regulates Human T Cell Function

  2012cited by this paper
• Necl-5/Poliovirus Receptor Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis

  2012cited by this paper
• The role of nectins in different types of cell–cell adhesion

  2012cited by this paper
• The Human Immunodeficiency Virus Type 1 Nef and Vpu Proteins Downregulate the Natural Killer Cell-Activating Ligand PVR

  2012cited by this paper
• Prognostic importance of tumour‐infiltrating memory T cells in oesophageal squamous cell carcinoma

  2012cited by this paper
• Vstm3 is a member of the CD28 family and an important modulator of T‐cell function

  2011cited by this paper
• Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

  2011cited by this paper
• CD155 on Human Vascular Endothelial Cells Attenuates the Acquisition of Effector Functions in CD8 T Cells

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Overexpression of Necl‐5 correlates with unfavorable prognosis in patients with lung adenocarcinoma

  2010cited by this paper
• The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

  2009cited by this paper
• A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression.

  2009cited by this paper
• Clinical importance of B7-H3 expression in human pancreatic cancer

  2009cited by this paper
• Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells1

  2009cited by this paper
• The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

  2009cited by this paper
• Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer

  2008cited by this paper
• Up on the tightrope: natural killer cell activation and inhibition

  2008cited by this paper
• Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs

  2008cited by this paper
• The CD155/poliovirus receptor enhances the proliferation of ras‐mutated cells

  2008cited by this paper
• The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin.

  2008cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer.

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.

  2006cited by this paper
• CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics.

  2005cited by this paper
• Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

  2005cited by this paper
• Inhibition of cell movement and proliferation by cell–cell contact-induced interaction of Necl-5 with nectin-3

  2005cited by this paper
• Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival.

  2005cited by this paper
• CD155/PVR plays a key role in cell motility during tumor cell invasion and migration

  2004cited by this paper
• Enhancement of Serum- and Platelet-derived Growth Factor-induced Cell Proliferation by Necl-5/Tage4/Poliovirus Receptor/CD155 through the Ras-Raf-MEK-ERK Signaling*

  2004cited by this paper
• CD226 (DNAM-1) Is Involved in Lymphocyte Function–associated Antigen 1 Costimulatory Signal for Naive T Cell Differentiation and Proliferation

  2003cited by this paper
• CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma.

  2003cited by this paper
• Nectin and afadin: novel organizers of intercellular junctions

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes.

  1996cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily.

  1989cited by this paper

• Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening.

  2026cites this paper
• Nectin-4 Tumor Expression as a Prognostic Factor and Potential Therapeutic Target in Stage II/III Rectal Cancer

  2025cites this paper
• CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse model

  2025cites this paper
• Prognostic and Predictive Significance of B7-H3 and CD155 Expression in Gastric Cancer Patients

  2025cites this paper
• CD155 density on target cells drives divergent natural killer cell responses owing to DNAM-1 loss

  2025cites this paper
• The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy

  2025cites this paper
• Troxerutin suppresses the stemness of osteosarcoma via the CD155/SRC/β-catenin signaling axis

  2025cites this paper
• Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors (Review)

  2025cites this paper
• CD155 as a prognostic and predictive biomarker in acute myeloid leukemia

  2025cites this paper
• The Significance of Nectin Family Proteins in Various Cancerogenous Processes

  2025influential citation
• CD155 promotes the progression of colorectal cancer by restraining CD8+ T cells via the PI3K/AKT/NF-κB pathway

  2025cites this paper
• Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy

  2025cites this paper
• CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors

  2025cites this paper
• NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors

  2025cites this paper
• Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape

  2024cites this paper
• Prognostic Relevance of Immunosuppressive CD155/TIGIT Signaling in Locally Advanced Rectal Cancer Patients With Neoadjuvant Chemoradiotherapy

  2024cites this paper
• Clinical significance of CD155 expression in surgically resected lung squamous cell carcinoma

  2024cites this paper
• nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer

  2024cites this paper
• Clinical significance and therapeutic implication of CD200 in pancreatic cancer.

  2024cites this paper
• Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy

  2024cites this paper
• Prognostic impact of nectin-like molecule-5 (CD155) expression in non-small cell lung cancer

  2024cites this paper
• The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy

  2024cites this paper
• Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling

  2024cites this paper
• The immunosuppressive landscape in tumor microenvironment

  2024cites this paper
• A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma

  2024cites this paper
• Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.

  2024cites this paper
• Poliovirus receptor inhibition in breast cancer cells induces antitumor immunity via T cell activation.

  2023cites this paper
• ADAR-mediated RNA editing regulates PVR immune checkpoint in colorectal cancer.

  2023cites this paper
• Clinical significance of serum CD155 levels in acute lymphoblastic leukemia patients

  2023cites this paper
• Detection of Pancreatic Ductal Adenocarcinoma-Associated Proteins in Serum

  2023cites this paper
• Single-cell RNA sequencing indicates cordycepin remodels the tumor immune microenvironment to enhance TIGIT blockade's anti-tumor effect in colon cancer.

  2023cites this paper
• The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways

  2023cites this paper
• CD155 and its receptors in cancer immune escape and immunotherapy.

  2023cites this paper
• CD155 and Its Receptors as Targets for Cancer Therapy

  2023cites this paper
• Novel targets for immune-checkpoint inhibition in cancer.

  2023cites this paper
• Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications

  2023cites this paper
• Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells.

  2023cites this paper
• Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcome in Patients with Pancreatic Cancer.

  2023cites this paper
• TIGIT, a novel immune checkpoint therapy for melanoma

  2023cites this paper
• Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer

  2023cites this paper
• Clinical significance of CD155 expression and correlation with cellular components of tumor microenvironment in gastric adenocarcinoma

  2023cites this paper
• Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

  2023cites this paper
• TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer

  2023cites this paper
• Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

  2023cites this paper
• Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes

  2022cites this paper
• PVR—A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma

  2022cites this paper
• The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients

  2022cites this paper
• CD155 immunohistochemical expression in upper tract urothelial carcinoma predicts poor prognosis.

  2022cites this paper
• Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives

  2022cites this paper
• Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

  2022cites this paper
• The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition

  2022cites this paper
• Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells

  2022cites this paper
• Immune cellular components and signaling pathways in the tumor microenvironment.

  2022cites this paper
• Emergence of the CD226 Axis in Cancer Immunotherapy

  2022cites this paper
• CD155 in tumor progression and targeted therapy.

  2022cites this paper
• TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry

  2022cites this paper
• Development of a recombinant oncolytic poliovirus type 3 strain with altered cell tropism

  2022cites this paper
• T-cell immunoglobulin and ITIM domain in cancer immunotherapy: A focus on tumor-infiltrating regulatory T cells.

  2022cites this paper
• CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis

  2022cites this paper
• Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy

  2022cites this paper
• Prognostic value of CD155/TIGIT expression in patients with colorectal cancer

  2022influential citation
• CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.

  2022cites this paper
• What Inhibits Natural Killers’ Performance in Tumour

  2022cites this paper
• CD155 promotes radioresistance and malignancy of esophageal cancer by regulating Hippo-YAP pathway

  2022cites this paper
• Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome

  2021cites this paper
• Targeting CD155 by rediocide-A overcomes tumour immuno-resistance to natural killer cells

  2021cites this paper
• CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers

  2021cites this paper
• TIGIT/CD226 Axis Regulates Anti-Tumor Immunity

  2021cites this paper
• Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis.

  2021cites this paper
• COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade

  2021cites this paper
• Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry

  2021cites this paper
• Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics

  2021cites this paper
• A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer

  2021cites this paper
• CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways

  2021cites this paper
• Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

  2021cites this paper
• Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry

  2021cites this paper
• Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma

  2021cites this paper
• Emerging roles of the nectin family of cell adhesion molecules in tumour-associated pathways.

  2021cites this paper
• TIGIT-Fc Promotes Antitumor Immunity

  2021cites this paper
• TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

  2021cites this paper
• Pancreatic Cancer and Immunotherapy: A Clinical Overview

  2021cites this paper
• CD155: A Key Receptor Playing Diversified Roles.

  2021cites this paper
• Immune checkpoint CD155 promoter methylation profiling reveals cancer-associated behaviors within breast neoplasia

  2021cites this paper
• Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

  2021cites this paper
• A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.

  2021cites this paper
• Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions

  2021cites this paper
• Abstract. CD155/T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a novel type of immune checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression and promotes the proliferative and migra-

  2021cites this paper
• Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D

  2020cites this paper
• Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma).

  2020cites this paper
• Overexpression of CD155 associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in microenvironment of breast cancer

  2020cites this paper
• Targeting CD155 on Myeloid Derived Suppressor Cells to Prevent Postoperative Immunosuppression in Cancer Patients

  2020cites this paper
• Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy

  2020cites this paper
• Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways.

  2020cites this paper
• Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes

  2020cites this paper
• An Enhancer-Based Analysis Revealed a New Function of Androgen Receptor in Tumor Cell Immune Evasion

  2020cites this paper
• TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro

  2020cites this paper
• Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion

  2020cites this paper
• CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

  2020influential citation
• Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution

  2020cites this paper
• The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.

  2020cites this paper